These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36932129)

  • 61. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study.
    El-Serag HB; Davila JA
    Hepatology; 2004 Mar; 39(3):798-803. PubMed ID: 14999699
    [TBL] [Abstract][Full Text] [Related]  

  • 62. State-of-the-art MR Imaging of Uncommon Hepatocellular Tumours: Fibrolamellar Hepatocellular Carcinoma and Combined Hepatocellularcholangiocarcinoma.
    Anysz-Grodzicka A; Podgorska J; Cieszanowski A
    Curr Med Imaging Rev; 2019; 15(3):269-280. PubMed ID: 31989878
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Small Nucleolar RNA Host Gene 18 Acts as a Tumor Suppressor and a Diagnostic Indicator in Hepatocellular Carcinoma.
    Liu XF; Thin KZ; Ming XL; Shuo-Li ; Ping-Luo ; Man-Zhu ; Li ND; Tu JC
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818794494. PubMed ID: 30126319
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular characteristics of fibrolamellar hepatocellular carcinoma.
    Patonai A; Erdélyi-Belle B; Korompay A; Somorácz A; Törzsök P; Kovalszky I; Barbai T; Rásó E; Lotz G; Schaff Z; Kiss A
    Pathol Oncol Res; 2013 Jan; 19(1):63-70. PubMed ID: 22872444
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Fibrolamellar hepatocellular carcinoma: a case report.
    Khoo JJ; Clouston A
    Malays J Pathol; 2001 Dec; 23(2):115-8. PubMed ID: 12166592
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A preclinical "magic bullet" against fibrolamellar hepatocellular carcinoma?
    Ducrot C; Piffoux M
    Mol Ther; 2024 Jan; 32(1):9-10. PubMed ID: 38104561
    [No Abstract]   [Full Text] [Related]  

  • 67. Case Report of Fibrolamellar Hepatocellular Carcinoma in A 15-Year-old Male.
    Alsadery HA; Almaiman H; Alibrah R; Mnayan M; Alblowi A; Alzayyat R; Alshahrani A
    Med Arch; 2022 Oct; 76(5):387-390. PubMed ID: 36545449
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases.
    Chagas AL; Kikuchi L; Herman P; Alencar RS; Tani CM; Diniz MA; Pugliese V; Rocha Mde S; D'Albuquerque LA; Carrilho FJ; Alves VA
    Clinics (Sao Paulo); 2015 Mar; 70(3):207-13. PubMed ID: 26017653
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Fibrolamellar hepatocellular carcinoma.
    Kwee HG
    Am Fam Physician; 1989 Aug; 40(2):175-7. PubMed ID: 2547295
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A case of fibrolamellar hepatocellular carcinoma.
    Kearney D; Donlon JB; Mendelson RM
    Australas Radiol; 1991 Feb; 35(1):88-91. PubMed ID: 1650180
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report.
    Tanaka K; Honna T; Kitano Y; Kuroda T; Tanaka K; Morikawa N; Matsuda H; Kawashima N; Matsuoka K; Miyauchi J
    J Clin Pathol; 2005 Aug; 58(8):884-7. PubMed ID: 16049296
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Hyperammonemic encephalopathy and fibrolamellar hepatocellular carcinoma].
    Berger C; Dimant P; Hermida L; Paulin F; Pereyra M; Tejo M
    Medicina (B Aires); 2012; 72(5):425-7. PubMed ID: 23089120
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Fibrolamellar liver cell cancer. A case report].
    Kahle M; Heilmann KL; Filler RD
    Z Gastroenterol; 1989 Jun; 27(6):341-3. PubMed ID: 2549740
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Connective tissue content of fibrolamellar carcinoma and other human liver tumors.
    Sárosi I; Kiss A; Schaff Z; Lapis K
    Acta Microbiol Hung; 1991; 39(4):321-31. PubMed ID: 1668900
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Fibrolamellar carcinoma of the liver.
    Yamaguchi R; Tajika T; Kanda H; Nakanishi K; Kawanishi J
    Hepatogastroenterology; 1999; 46(27):1706-9. PubMed ID: 10430327
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
    Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
    Oncol Res Treat; 2022; 45(7-8):430-437. PubMed ID: 35537414
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA.
    Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM
    Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A case of fibrolamellar cancer with a palliative response and minor radiographic regression with erlotinib and bevacizumab combination therapy.
    Fakih M
    Am J Ther; 2014; 21(6):e207-10. PubMed ID: 23676344
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Fibrolamellar hepatocellular carcinoma with biliary tumor thrombus: an unreported association.
    De Gaetano AM; Nure E; Grossi U; Frongillo F; Russo R; Vecchio FM; Lirosi MC; Sganga G; Felice C; Bonomo L; Agnes S
    Jpn J Radiol; 2013 Oct; 31(10):706-12. PubMed ID: 23852711
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.
    Graham RP; Terracciano LM; Meves A; Vanderboom PM; Dasari S; Yeh MM; Torbenson MS; Cruise MW
    Mod Pathol; 2016 Jun; 29(6):607-15. PubMed ID: 27015136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.